Douglas Larson: So, $25 million is the annual number if you pull out Cancer. So that was — the $9 million is an increase versus last year. So it’s not the absolute number that we’re looking at, right? We did have three months of Cancer last year. We’ve got 12 this year. Keep in mind that we are going to continue to consolidate Cancer into our numbers as well. So I don’t know if you’re trying to pull those numbers apart. It might be a little bit tricky. We could maybe follow-up on that one, if that works.
Marie Thibault: Okay. Certainly. Happy to follow-up later. Thanks for taking the questions.
Steve Lisi: Thanks, Marie.
Operator: Our next question comes from the line of Matt Kaplan with Ladenburg Thalmann. Please proceed with your question.
Matt Kaplan: Hi. Thanks for taking the questions. Just staying with the LungFit PH, I guess, now that you’ve completed phase 1 of the launch, can you tell us a little bit more about what you accomplished in phase 1, specifically maybe some more detail around the number of contracts? And then, with that, what we should look for as you now launch into the second phase of the commercial program here?
Steve Lisi: So, Matt, I’m going to let Duncan talk about what we’ve learned and what’s going to help us going forward. But with respect to the number of contracts, I mean, we did state that we had multiple contracts that have been signed. I would say that the number as we see here today is less than 10. So, we’re looking at single digit number of contracts. And going forward, obviously, we expect that number to increase quite dramatically over the next four to six quarters. I mean, as we bring more people on and we are able to handle more volume of customers, it is going to increase significantly. And that was always the plan with our three-step process towards this launch as we’ve had in our slides for the past 18 months and we’ve been stating on every quarterly conference call that phase 1 would be where we learn and make sure everything we have is up to speed, ready to go to expand.
And now we’re in phase 2 where we’re going to expand our team and start to take some serious market share. It’s how I look at it. But Duncan, you want to comment on what we’ve learned in phase 1?
Duncan Fatkin: Yes. Thanks for the question, Matt. So, I mean, our focus has been on making sure that the logistics smooth, the clinical performance is as we’d expected and the training and everything associated with that continues to go well, which we definitely feel good about that. Certainly, the feedback continues to be that our system is very simple to use and it doesn’t take too long to do the training. We’ve been refining some of our programs because in the simplicity and ease, sometimes actually a lot of the clinicians using the device don’t spend as much time as we’d like them to. And so, we kind of do some remedial work. And so, we refine our program. We certainly also understood better the profile of the hospitals that we need to go to, to make sure that we pick the ideal locations and the ideal partners, which is why we took our time to go to a variety of different types of hospitals.
So from our perspective, that probably the main learnings, nothing that has been shocking to us, and definitely some optimization that we’ve done with the device. So, we’re pleased with what we’ve learned and now we can really start to expand with, I’ll call it, much more confidence.
